- |||||||||| dexamethasone / Generic mfg.
Journal: Cardiomyocyte-targeted anti-inflammatory nanotherapeutics against myocardial ischemia reperfusion (IR) injury. (Pubmed Central) - Aug 3, 2022 Herein, cardiomyocyte-targeted nanotherapeutics were developed for the reactive oxygen species (ROS)-ultrasensitive co-delivery of dexamethasone (Dex) and RAGE small interfering RNA (siRAGE) to attenuate myocardial inflammation...Therefore, the current nanotherapeutics represent an effective example for the co-delivery and on-demand release of nucleic acid and chemodrug payloads, and might find promising utilities toward the synergistic management of myocardial inflammation. Supplementary material (experimental methods, RNA and primer sequences, H NMR spectra, FTIR spectrum, TEM images, zeta potential, drug loading content, RNA and drug release, cytotoxicity, etc.) is available in the online version of this article at 10.1007/s12274-022-4553-6.
- |||||||||| budesonide/formoterol / Generic mfg.
Trial completion, Trial completion date: As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period (clinicaltrials.gov) - Aug 3, 2022 P3, N=31, Completed, Supplementary material (experimental methods, RNA and primer sequences, H NMR spectra, FTIR spectrum, TEM images, zeta potential, drug loading content, RNA and drug release, cytotoxicity, etc.) is available in the online version of this article at 10.1007/s12274-022-4553-6. Recruiting --> Completed | Trial completion date: Dec 2022 --> May 2022
- |||||||||| ceftriaxone / Generic mfg., prednisolone / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg.
Journal: Whipple's disease with normal duodenal histology diagnosed by ileal biopsy using balloon endoscopy. (Pubmed Central) - Aug 3, 2022 The patient was treated with intravenous ceftriaxone and oral trimethoprim-sulfamethoxazole, and her symptoms improved one month after treatment. Balloon endoscopy performed 32 months later revealed complete improvement in lesions of the ileum.
- |||||||||| ropivacaine / Generic mfg.
Preclinical, Journal: PLGA-based microspheres containing ropivacaine and betamethasone for sciatic nerve block in mice. (Pubmed Central) - Aug 3, 2022 In an in vitro study of drug release, it can be concluded that the RPC/BTM PLGA MS exhibited sustained and long-term release properties for 16 days. Furthermore, the result of an in vivo study indicated that the RPC/BTM PLGA MS had sustained release effect and the pharmacodynamics result showed that preparing RPC/BTM PLGA MS as microsphere preparation could not only extend the drug effect time but also prolong the duration of local anesthetics compared with the common RPC PLGA MS.
- |||||||||| budesonide / Generic mfg.
Journal: Microscopic colitis: Etiopathology, diagnosis, and rational management. (Pubmed Central) - Aug 2, 2022 In microscopic colitis induced by checkpoint inhibitors, a drug class used increasingly for a wide range of malignancies, a more aggressive therapeutic approach with biologics introduced early seems reasonable. However, particular attention needs to be drawn to the existence of incomplete forms of microscopic colitis with the risk of being overlooked in routine clinical settings.
- |||||||||| hydrocortisone / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Aug 2, 2022 P1, N=8, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2022 --> Jul 2023
- |||||||||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Late Breaking Abstract - THE ROLE OF LABACS IN LONG COVID-19 PATIENTS IN PRINGSEWU, IND0NESIA (TP-20 in thematic poster area) - Aug 1, 2022 - Abstract #ERS2022ERS_4980; COVID-19 can result in severe outcomes; understanding treatment and severity trends can improve prognosis. LABACS treatment improved lung function and clinically benefit in managing obstruction due to COVID-19.
- |||||||||| dexamethasone / Generic mfg.
The Effects of a Radiation Oncology Emergencies Lecture on Initiation of Care, Timeliness of Consultations Placed and Duration of Hospitalization (Henry B. Gonzalez Convention Center, Room 007 A/B) - Aug 1, 2022 - Abstract #ASTRO2022ASTRO_495; Such initiatives should be widespread at all hospitals to improve the outcomes of hospitalized cancer patients. Metric Pre-Lecture (2019-2020) Post-Lecture (2021-2022) p-value Time to Consultation - Mean 65.8 hours 38.3 hours 0.018 Time to Consultation – Median (Range) 42.6 (0 to 279.9) hours 34.5 (0 to 92.5) hours Time to Dexamethasone Initiation - Mean 22.8 hours 18.4 hours 0.661 Time to Dexamethasone Initiation – Median (Range) 12.6 (1 to 92.8) hours 9.3 (1 to 97.8) hours Duration of Hospitalization - Mean 13.7 days 8.9 days 0.016 Duration of Hospitalization – Median (Range) 11 (0 to 34) days 7 (1 to 31) days
|